Nirmatrelvir/ritonavir: real world drug-drug interaction management experience

被引：0
|
作者：
Bukhari, Shahid [1 ]
Hughes, Stephen [1 ]
Mughal, Nabeela [1 ]
Moore, Luke S. P. [1 ,2 ,3 ]
Davies, Gary [1 ]
Zhang, Adrian Varghas [2 ]
Ng, Megan [2 ]
Karagozlu, Zekiye [2 ]
Boffito, Marta [1 ,2 ]
机构：
[1] Chelsea & Westminster Hosp Fdn Trust, London, England
[2] Imperial Coll London, London, England
[3] Imperial Coll Healthcare NHS Trust, North West London Pathol, London, England
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2024年 / 22卷 / 09期
关键词：
Nirmatrelvir/ritonavir; drug-drug interactions; COVID-19; Paxlovid; real world;
D O I：
10.1080/14787210.2024.2389884
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
BackgroundIn the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions.Research design and methodsWe analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.ResultsAmong 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.ConclusionsThis highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.
引用
收藏
页码：781 / 783
页数：3
相关论文
共 50 条
  • [41] Pharmacokinetic drug-drug interaction analysis of pyramax® and ritonavir in healthy volunteers
    Duparc, S.
    Borghini-Fuhrer, I.
    Fleckenstein, L.
    Jung, D.
    Lopez-Lazaro, L.
    Methaneethorn, J.
    Morris, C.
    Pokorny, R.
    Shin, C. -S.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 : 138 - 138
  • [42] Nirmatrelvir+ritonavir/Tacrolimus interactionDrug toxicity following drug interaction
    Reactions Weekly, 2024, 2002 (1) : 379 - 379
  • [43] A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19
    Tomida, Takeshi
    Itohara, Kotaro
    Yamamoto, Kazuhiro
    Kimura, Takeshi
    Fujita, Kohei
    Uda, Atsushi
    Kitahiro, Yumi
    Yokoyama, Naoki
    Hyodo, Yoji
    Omura, Tomohiro
    Yano, Ikuko
    DRUG METABOLISM AND PHARMACOKINETICS, 2023, 53
  • [44] Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
    Lemaitre, Florian
    Gregoire, Matthieu
    Monchaud, Caroline
    Bouchet, Stephane
    Saint-Salvi, Beatrice
    Polard, Elisabeth
    Benaboud, Sihem
    Chouchana, Laurent
    Cracowski, Jean-Luc
    Drici, Milou-Daniel
    Garraffo, Rodolphe
    Guilhaumou, Romain
    Jonville-Bera, Annie-Pierre
    Molimard, Mathieu
    Muret, Patric
    Peytavin, Gilles
    Richard, Vincent
    Solas, Caroline
    THERAPIE, 2022, 77 (05): : 509 - 521
  • [45] Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
    Lemaitre, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 7 - 7
  • [46] PAH Therapy In HIV: Lack Of Drug-Drug Interaction Between Ambrisentan And Ritonavir
    Gillies, H. C.
    Wang, X.
    Staehr, P.
    Zack, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [47] RITONAVIR INHIBITS PRASUGREL IN VITRO BIOACTIVATION: A POTENTIAL PHARMACOKINETIC DRUG-DRUG INTERACTION
    Ancrenaz, V.
    Daali, Y.
    Samer, C.
    Dayer, P.
    Desmeules, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S56 - S56
  • [48] Contextualized Drug-Drug Interaction Management Improves Clinical Utility Compared With Basic Drug-Drug Interaction Management in Hospitalized Patients
    Wasylewicz, Arthur T. M.
    van de Burgt, Britt W. M.
    Manten, Thomas
    Kerskes, Marieke
    Compagner, Wilma N.
    Korsten, Erik H. M.
    Egberts, Toine C. G.
    Grouls, Rene J. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (02) : 382 - 390
  • [49] Drug-drug interaction between ritonavir and inhaled corticoid leading to hypercorticism in a child
    Logerot, S.
    Lepelley, M.
    Villier, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 58 - 58
  • [50] LACK OF DRUG-DRUG INTERACTION BETWEEN MERICITABINE AND RITONAVIR-BOOSTED DANOPREVIR
    Moreira, S.
    Goelzer, P.
    Weigl, P.
    Badman, E.
    Poirer, A.
    Brennan, B. J.
    Chen, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S22 - S22
12345